These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
253 related items for PubMed ID: 17694552
21. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy. Voravud N, Sriuranpong V. J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676 [Abstract] [Full Text] [Related]
22. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C. J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009 [Abstract] [Full Text] [Related]
23. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy. Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, Jaeger C. Curr Med Res Opin; 2011 Feb; 27(2):355-63. PubMed ID: 21166611 [Abstract] [Full Text] [Related]
24. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K. Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916 [Abstract] [Full Text] [Related]
25. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P. Am J Nephrol; 2006 Sep; 26(2):149-56. PubMed ID: 16636531 [Abstract] [Full Text] [Related]
26. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF. J Clin Oncol; 2008 May 10; 26(14):2342-9. PubMed ID: 18467726 [Abstract] [Full Text] [Related]
27. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Bastit L, Vandebroek A, Altintas S, Gaede B, Pintér T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF. J Clin Oncol; 2008 Apr 01; 26(10):1611-8. PubMed ID: 18375890 [Abstract] [Full Text] [Related]
32. Phase III clinical trials with darbepoetin: implications for clinicians. Glaspy J. Best Pract Res Clin Haematol; 2005 Apr 01; 18(3):407-16. PubMed ID: 15792914 [Abstract] [Full Text] [Related]
33. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F. Nefrologia; 2003 Apr 01; 23(2):114-24. PubMed ID: 12778875 [Abstract] [Full Text] [Related]
34. The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo). Hejaili F. Saudi J Kidney Dis Transpl; 2009 Jul 01; 20(4):590-5. PubMed ID: 19587498 [Abstract] [Full Text] [Related]
35. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S. Am J Nephrol; 2004 Jul 01; 24(4):453-60. PubMed ID: 15331889 [Abstract] [Full Text] [Related]
36. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. 20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G. J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026 [Abstract] [Full Text] [Related]
37. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness. Voils SA, Harpe SH, Brophy GM. Pharmacotherapy; 2007 Apr 20; 27(4):535-41. PubMed ID: 17381380 [Abstract] [Full Text] [Related]
38. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P. Eur Heart J; 2007 Sep 20; 28(18):2208-16. PubMed ID: 17681958 [Abstract] [Full Text] [Related]
39. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K. J Am Coll Cardiol; 2007 Feb 20; 49(7):753-62. PubMed ID: 17306703 [Abstract] [Full Text] [Related]
40. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer. Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F. Lung Cancer; 2004 Oct 20; 46(1):119-24. PubMed ID: 15364140 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]